Pfizer

Pfizer snaps up Biohaven’s migraine drug for $1.24bn

Pfizer will sell the migraine drug outside the US and will also gain the rights to a second drug. ... Moving forwards, Biohaven will continue to lead research and development globally and Pfizer will execute commercialisation globally, outside the US.

Pfizer's oral antiviral Paxlovid significantly cuts risk of severe COVID-19

The therapy also shows 'potent antiviral in vitro activity' against variants of concern, said Pfizer. ... Pfizer has committed to 'equitable access' at an affordable price through a tiered pricing approach based on the income level of each country.

Pfizer's 2021 revenue predictions soar to $82bn

Strong third-quarter revenues of $24.1bn lifted by sales of its BioNTech-partnered COVID-19 vaccine Comirnaty see Pfizer raise its 2021 revenue guidance to $82bn. ... Pfizer is having a good year. Following third-quarter sales figures that beat even the

Novartis invests $1.3bn in protein degradation technology

In July, Pfizer paid $1bn upfront to Arvinas (plus an additional $1.4bn in future milestone payments and a share of profits) for ARV-471, a breast cancer candidate currently in

Novartis receives approval for third-generation leukaemia therapy

This indication was supported by data from the pivotal phase 3 ASCEMBL trial, where Scemblix demonstrated significant and clinically meaningful superiority over Pfizer’s second-generation treatment Bosulif (bosutinib).

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]